Gastrointestinal (GI) cancer, which refers to cancer that affects the digestive system, is among the most common cancer types with high morbidity and mortality. The most common types of GI cancers are as follows: gastric cancer, colorectal cancer, pancreatic cancer, esophageal cancer, and liver cancer. Due to local tissue invasion and metastasis, radiation therapy and chemotherapy affect the length or quality of life of patients with advanced GI cancer insignificantly. There is no way to prevent GI cancers completely, but a healthy lifestyle can help reduce the risk for GI cancer. Stop smoking, limit, or avoid alcohol, regular exercise, a low-fat diet high in fruit and vegetables can reduce the risk for GI cancer.
The Research Topic aims to discover novel anticancer molecules for gastrointestinal carcinoma (in vitro and in vivo) and provide a basis for developing new anticancer drugs. Anticancer molecules that cover a wide range can be natural compounds, chemically synthesized compounds, clinical medicines, and other bioactivity substances.
The Topic Editors welcome original research articles, reviews, opinions, and perspective articles including but not limited to the following themes:
• To comprehensively illuminate the pharmacological mechanism of anticancer molecules using multi-omics (such as transcriptomics, proteomics, phosphoryl-omics, and metabonomics)
• To investigate the cell death pathways in which anticancer molecules cause cancer cells to die and elucidate the molecular mechanisms (such as apoptosis, necroptosis, autophagy, pyroptosis, and ferroptosis). We strongly encourage authors to dig deeply for the subtype of cell death, for example, to study aggrephagy, mitophagy, and xenophagy of cancer cells in autophagy.
• To reveal the anticancer pharmacological mechanism of the interaction between drug (or candidate) and oncoprotein (or tumor suppressor). Both computer simulation data and wet experimental data are highly recommended.
• Anticancer drug candidates (or beneficial microorganisms and secondary metabolites) improve the immune microenvironment by modulating intestinal flora to combat gastrointestinal tumors.
Note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Gastrointestinal (GI) cancer, which refers to cancer that affects the digestive system, is among the most common cancer types with high morbidity and mortality. The most common types of GI cancers are as follows: gastric cancer, colorectal cancer, pancreatic cancer, esophageal cancer, and liver cancer. Due to local tissue invasion and metastasis, radiation therapy and chemotherapy affect the length or quality of life of patients with advanced GI cancer insignificantly. There is no way to prevent GI cancers completely, but a healthy lifestyle can help reduce the risk for GI cancer. Stop smoking, limit, or avoid alcohol, regular exercise, a low-fat diet high in fruit and vegetables can reduce the risk for GI cancer.
The Research Topic aims to discover novel anticancer molecules for gastrointestinal carcinoma (in vitro and in vivo) and provide a basis for developing new anticancer drugs. Anticancer molecules that cover a wide range can be natural compounds, chemically synthesized compounds, clinical medicines, and other bioactivity substances.
The Topic Editors welcome original research articles, reviews, opinions, and perspective articles including but not limited to the following themes:
• To comprehensively illuminate the pharmacological mechanism of anticancer molecules using multi-omics (such as transcriptomics, proteomics, phosphoryl-omics, and metabonomics)
• To investigate the cell death pathways in which anticancer molecules cause cancer cells to die and elucidate the molecular mechanisms (such as apoptosis, necroptosis, autophagy, pyroptosis, and ferroptosis). We strongly encourage authors to dig deeply for the subtype of cell death, for example, to study aggrephagy, mitophagy, and xenophagy of cancer cells in autophagy.
• To reveal the anticancer pharmacological mechanism of the interaction between drug (or candidate) and oncoprotein (or tumor suppressor). Both computer simulation data and wet experimental data are highly recommended.
• Anticancer drug candidates (or beneficial microorganisms and secondary metabolites) improve the immune microenvironment by modulating intestinal flora to combat gastrointestinal tumors.
Note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.